Intravenous fluids in sepsis - not exactly a rare treatment in a niche condition. Rapidly catch-up on this weeks journal club at the link for the take-home points.
This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Intravenous fluids in sepsis - not exactly a rare treatment in a niche condition. Rapidly catch-up on this weeks journal club at the link for the take-home points.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) August 11, 2022
At journal club this week, a question that impacts all intensivists - when patients with septic shock need ongoing resuscitation after their initial 30cc/kg treatment, what strategy for intravenous fluid volume should we use?
Find out in thread👇 pic.twitter.com/z0pMmEp732